Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Posted by on Jun 10th, 2026

Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 218,904 shares, an increase of 478.3% from the May 14th total of 37,850 shares. Approximately 10.6% of the company’s stock are sold short. Based on an average trading volume of 5,443,245 shares, the short-interest ratio is currently 0.0 days.

Artelo Biosciences Stock Performance

Artelo Biosciences stock opened at $1.33 on Wednesday. Artelo Biosciences has a fifty-two week low of $1.19 and a fifty-two week high of $85.80. The stock has a market cap of $3.10 million, a PE ratio of -0.04 and a beta of -0.13. The firm’s 50-day simple moving average is $3.56 and its 200 day simple moving average is $4.33.

Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($4.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($3.22).

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ARTL. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Friday, March 27th. Wall Street Zen raised shares of Artelo Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $54.00.

Get Our Latest Research Report on Artelo Biosciences

Artelo Biosciences Company Profile

(Get Free Report)

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.

Featured Stories

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.